Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Стабильная стенокардия и частота сердечных сокращений
Стабильная стенокардия и частота сердечных сокращений
Кириченко А.А. Стабильная стенокардия и частота сердечных сокращений. CardioСоматика. 2018; 9 (3): 25–29. DOI: 10.26442/2221-7185_2018.3.25-29
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Неблагоприятное влияние высокой частоты сердечных сокращений (ЧСС) на течение ишемической болезни сердца (ИБС) хорошо известно. Высокая ЧСС может приводить к несоответствию между возросшей потребностью миокарда в кислороде и способностью к адекватному увеличению коронарного кровотока. Приведен обзор исследований, направленных на изучение возможности урежения ЧСС снижать количество приступов стенокардии у пациентов с ИБС, влиять на риск смерти и сердечно-сосудистых осложнений. Показано, что ограничение ЧСС при стенокардии улучшает самочувствие пациентов, переносимость ими физических нагрузок. Однако не все классы препаратов оказывают влияние на прогноз ИБС.
Ключевые слова: ишемическая болезнь сердца, частота сердечных сокращений, стабильная стенокардия.
However, not all classes of drugs affect the prognosis of IHD.
Key words: ischemic heart disease, heart rate, stable angina.
Ключевые слова: ишемическая болезнь сердца, частота сердечных сокращений, стабильная стенокардия.
________________________________________________
However, not all classes of drugs affect the prognosis of IHD.
Key words: ischemic heart disease, heart rate, stable angina.
Полный текст
Список литературы
1. Морган-мл. Дж.Э., Михаил М.С. Клиническая анестезиология. Книга вторая. Пер. с англ. под ред. А.А.Бунятяна. М.: БИНОМ, 2000. / Morgan-ml. Dzh.E., Mikhail M.S. Klinicheskaia anesteziologiia. Kniga vtoraia. Per. s angl. pod red. A.A.Buniatiana. M.: BINOM, 2000. [in Russian]
2. Di Francesco D, Camm A. Heart rate lowering by specific and selective if current inhibition with ivabradin. Drugs 2004; 64 (16): 1757–65.
3. The b-Blocker Pooling Project Research Group. The beta-blocker pooling project (BBPP): subgroup findings from randomized trial in post infarction patients. Eur Heart J 1988; 9: 8–16.
4. Steg PG, Himbert D. Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J 2005; 7 (Suppl. H): h7–h15.
5. Стрюк Р.И. Клиническое обоснование применения фиксированной комбинации бисопролола с амлодипином при артериальной гипертонии. Consilium Medicum. 2013; 15 (1). / Striuk R.I. Klinicheskoe obosnovanie primeneniia fiksirovannoi kombinatsii bisoprolola s amlodipinom pri arterial'noi gipertonii. Consilium Medicum. 2013; 15 (1). [in Russian]
6. Borer J, Fox K, Jaillon P, Lerebours G. Ivabradine Investigators Group. Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo controlled trial. Circulation 2003; 107: 817–23.
7. Tardiff J, Ford I, Tendera M for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529–36.
8. Ruzyllo W, Ford I, Tendera M et al. Antianginal and anti-ischemic effects of If current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: a 3-month randomized, controlled, double-blind, multicenter trial. Drugs 2007; 67 (3): 393–405.
9. Лебедь Е.И., Крючкова О.Н. Использование препарата Кораксан как новое направление в лечении ишемической болезни сердца. Крымский терапевт. журн. 2009; 1: 52–4. / Lebed' E.I., Kriuchkova O.N. Ispol'zovanie preparata Koraksan kak novoe napravlenie v lechenii ishemicheskoi bolezni serdtsa. Krymskii terapevt. zhurn. 2009; 1: 52–4. [in Russian]
10. Tardif JC, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
11. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372: 807–16.
12. Fox K, Ford I, Steg PG et al; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817–21.
13. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85.
14. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11–22.
15. Лопатин Ю.М. Оценка антиангинальной эффективности ивабрадина у больных ишемической болезнью сердца, осложненной сердечной недостаточностью. Кардиология. 2015; 5: 5–11. / Lopatin Iu.M. Otsenka antianginal'noi effektivnosti ivabradina u bol'nykh ishemicheskoi bolezn'iu serdtsa, oslozhnennoi serdechnoi nedostatochnost'iu. Kardiologiia. 2015; 5: 5–11. [in Russian]
16. Глезер М.Г. От лица участников программы ЛИНКОР. Влияние терапии ивабрадином на качество жизни пациентов со стабильной формой ишемической болезни сердца: результаты программы ЛИНКОР. Кардиология. 2015; 2: 4–9. / Glezer M.G. Ot litsa uchastnikov programmy LINKOR. Vliianie terapii ivabradinom na kachestvo zhizni patsientov so stabil'noi formoi ishemicheskoi bolezni serdtsa: rezul'taty programmy LINKOR. Kardiologiia. 2015; 2: 4–9. [in Russian]
17. Карпов Ю.А., Глезер М.Г., Васюк Ю.А. и др. Антиангинальная эффективность и переносимость ивабрадина в терапии пациентов со стабильной стенокардией: результаты исследования КОНТРОЛЬ-2. Кардиоваск. терапия и профилактика. 2011; 10 (8): 83–9. / Karpov Iu.A., Glezer M.G., Vasiuk Iu.A. i dr. Antianginal'naia effektivnost' i perenosimost' ivabradina v terapii patsientov so stabil'noi stenokardiei: rezul'taty issledovaniia KONTROL-2. Kardiovask. terapiia i profilaktika. 2011; 10 (8): 83–9. [in Russian]
2. Di Francesco D, Camm A. Heart rate lowering by specific and selective if current inhibition with ivabradin. Drugs 2004; 64 (16): 1757–65.
3. The b-Blocker Pooling Project Research Group. The beta-blocker pooling project (BBPP): subgroup findings from randomized trial in post infarction patients. Eur Heart J 1988; 9: 8–16.
4. Steg PG, Himbert D. Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J 2005; 7 (Suppl. H): h7–h15.
5. Striuk R.I. Klinicheskoe obosnovanie primeneniia fiksirovannoi kombinatsii bisoprolola s amlodipinom pri arterial'noi gipertonii. Consilium Medicum. 2013; 15 (1). [in Russian]
6. Borer J, Fox K, Jaillon P, Lerebours G. Ivabradine Investigators Group. Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo controlled trial. Circulation 2003; 107: 817–23.
7. Tardiff J, Ford I, Tendera M for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529–36.
8. Ruzyllo W, Ford I, Tendera M et al. Antianginal and anti-ischemic effects of If current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: a 3-month randomized, controlled, double-blind, multicenter trial. Drugs 2007; 67 (3): 393–405.
9. Lebed' E.I., Kriuchkova O.N. Ispol'zovanie preparata Koraksan kak novoe napravlenie v lechenii ishemicheskoi bolezni serdtsa. Krymskii terapevt. zhurn. 2009; 1: 52–4. [in Russian]
10. Tardif JC, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
11. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372: 807–16.
12. Fox K, Ford I, Steg PG et al; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817–21.
13. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85.
14. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11–22.
15. Lopatin Iu.M. Otsenka antianginal'noi effektivnosti ivabradina u bol'nykh ishemicheskoi bolezn'iu serdtsa, oslozhnennoi serdechnoi nedostatochnost'iu. Kardiologiia. 2015; 5: 5–11. [in Russian]
16. Glezer M.G. Ot litsa uchastnikov programmy LINKOR. Vliianie terapii ivabradinom na kachestvo zhizni patsientov so stabil'noi formoi ishemicheskoi bolezni serdtsa: rezul'taty programmy LINKOR. Kardiologiia. 2015; 2: 4–9. [in Russian]
17. Karpov Iu.A., Glezer M.G., Vasiuk Iu.A. i dr. Antianginal'naia effektivnost' i perenosimost' ivabradina v terapii patsientov so stabil'noi stenokardiei: rezul'taty issledovaniia KONTROL-2. Kardiovask. terapiia i profilaktika. 2011; 10 (8): 83–9. [in Russian]
2. Di Francesco D, Camm A. Heart rate lowering by specific and selective if current inhibition with ivabradin. Drugs 2004; 64 (16): 1757–65.
3. The b-Blocker Pooling Project Research Group. The beta-blocker pooling project (BBPP): subgroup findings from randomized trial in post infarction patients. Eur Heart J 1988; 9: 8–16.
4. Steg PG, Himbert D. Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J 2005; 7 (Suppl. H): h7–h15.
5. Стрюк Р.И. Клиническое обоснование применения фиксированной комбинации бисопролола с амлодипином при артериальной гипертонии. Consilium Medicum. 2013; 15 (1). / Striuk R.I. Klinicheskoe obosnovanie primeneniia fiksirovannoi kombinatsii bisoprolola s amlodipinom pri arterial'noi gipertonii. Consilium Medicum. 2013; 15 (1). [in Russian]
6. Borer J, Fox K, Jaillon P, Lerebours G. Ivabradine Investigators Group. Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo controlled trial. Circulation 2003; 107: 817–23.
7. Tardiff J, Ford I, Tendera M for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529–36.
8. Ruzyllo W, Ford I, Tendera M et al. Antianginal and anti-ischemic effects of If current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: a 3-month randomized, controlled, double-blind, multicenter trial. Drugs 2007; 67 (3): 393–405.
9. Лебедь Е.И., Крючкова О.Н. Использование препарата Кораксан как новое направление в лечении ишемической болезни сердца. Крымский терапевт. журн. 2009; 1: 52–4. / Lebed' E.I., Kriuchkova O.N. Ispol'zovanie preparata Koraksan kak novoe napravlenie v lechenii ishemicheskoi bolezni serdtsa. Krymskii terapevt. zhurn. 2009; 1: 52–4. [in Russian]
10. Tardif JC, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
11. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372: 807–16.
12. Fox K, Ford I, Steg PG et al; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817–21.
13. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85.
14. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11–22.
15. Лопатин Ю.М. Оценка антиангинальной эффективности ивабрадина у больных ишемической болезнью сердца, осложненной сердечной недостаточностью. Кардиология. 2015; 5: 5–11. / Lopatin Iu.M. Otsenka antianginal'noi effektivnosti ivabradina u bol'nykh ishemicheskoi bolezn'iu serdtsa, oslozhnennoi serdechnoi nedostatochnost'iu. Kardiologiia. 2015; 5: 5–11. [in Russian]
16. Глезер М.Г. От лица участников программы ЛИНКОР. Влияние терапии ивабрадином на качество жизни пациентов со стабильной формой ишемической болезни сердца: результаты программы ЛИНКОР. Кардиология. 2015; 2: 4–9. / Glezer M.G. Ot litsa uchastnikov programmy LINKOR. Vliianie terapii ivabradinom na kachestvo zhizni patsientov so stabil'noi formoi ishemicheskoi bolezni serdtsa: rezul'taty programmy LINKOR. Kardiologiia. 2015; 2: 4–9. [in Russian]
17. Карпов Ю.А., Глезер М.Г., Васюк Ю.А. и др. Антиангинальная эффективность и переносимость ивабрадина в терапии пациентов со стабильной стенокардией: результаты исследования КОНТРОЛЬ-2. Кардиоваск. терапия и профилактика. 2011; 10 (8): 83–9. / Karpov Iu.A., Glezer M.G., Vasiuk Iu.A. i dr. Antianginal'naia effektivnost' i perenosimost' ivabradina v terapii patsientov so stabil'noi stenokardiei: rezul'taty issledovaniia KONTROL-2. Kardiovask. terapiia i profilaktika. 2011; 10 (8): 83–9. [in Russian]
________________________________________________
2. Di Francesco D, Camm A. Heart rate lowering by specific and selective if current inhibition with ivabradin. Drugs 2004; 64 (16): 1757–65.
3. The b-Blocker Pooling Project Research Group. The beta-blocker pooling project (BBPP): subgroup findings from randomized trial in post infarction patients. Eur Heart J 1988; 9: 8–16.
4. Steg PG, Himbert D. Unmet medical needs and therapeutic opportunities in stable angina. Eur Heart J 2005; 7 (Suppl. H): h7–h15.
5. Striuk R.I. Klinicheskoe obosnovanie primeneniia fiksirovannoi kombinatsii bisoprolola s amlodipinom pri arterial'noi gipertonii. Consilium Medicum. 2013; 15 (1). [in Russian]
6. Borer J, Fox K, Jaillon P, Lerebours G. Ivabradine Investigators Group. Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo controlled trial. Circulation 2003; 107: 817–23.
7. Tardiff J, Ford I, Tendera M for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529–36.
8. Ruzyllo W, Ford I, Tendera M et al. Antianginal and anti-ischemic effects of If current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: a 3-month randomized, controlled, double-blind, multicenter trial. Drugs 2007; 67 (3): 393–405.
9. Lebed' E.I., Kriuchkova O.N. Ispol'zovanie preparata Koraksan kak novoe napravlenie v lechenii ishemicheskoi bolezni serdtsa. Krymskii terapevt. zhurn. 2009; 1: 52–4. [in Russian]
10. Tardif JC, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
11. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo controlled trial. Lancet 2008; 372: 807–16.
12. Fox K, Ford I, Steg PG et al; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817–21.
13. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85.
14. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11–22.
15. Lopatin Iu.M. Otsenka antianginal'noi effektivnosti ivabradina u bol'nykh ishemicheskoi bolezn'iu serdtsa, oslozhnennoi serdechnoi nedostatochnost'iu. Kardiologiia. 2015; 5: 5–11. [in Russian]
16. Glezer M.G. Ot litsa uchastnikov programmy LINKOR. Vliianie terapii ivabradinom na kachestvo zhizni patsientov so stabil'noi formoi ishemicheskoi bolezni serdtsa: rezul'taty programmy LINKOR. Kardiologiia. 2015; 2: 4–9. [in Russian]
17. Karpov Iu.A., Glezer M.G., Vasiuk Iu.A. i dr. Antianginal'naia effektivnost' i perenosimost' ivabradina v terapii patsientov so stabil'noi stenokardiei: rezul'taty issledovaniia KONTROL-2. Kardiovask. terapiia i profilaktika. 2011; 10 (8): 83–9. [in Russian]
Авторы
А.А.Кириченко
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
andrey.apollonovich@yandex.ru
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
andrey.apollonovich@yandex.ru
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
andrey.apollonovich@yandex.ru
________________________________________________
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
andrey.apollonovich@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.